Search Results - "Qian, Kewen"

  • Showing 1 - 15 results of 15
Refine Results
  1. 1

    Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig by Lei, Changhai, Qian, Kewen, Li, Tian, Zhang, Sheng, Fu, Wenyan, Ding, Min, Hu, Shi

    Published in Nature communications (24-04-2020)
    “…Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, at the end of 2019, and there are currently no specific antiviral…”
    Get full text
    Journal Article
  2. 2

    CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity by Fu, Wenyan, Lei, Changhai, Liu, Shuowu, Cui, Yingshu, Wang, Chuqi, Qian, Kewen, Li, Tian, Shen, Yafeng, Fan, Xiaoyan, Lin, Fangxing, Ding, Min, Pan, Mingzhu, Ye, Xuting, Yang, Yongji, Hu, Shi

    Published in Nature communications (25-09-2019)
    “…Genetically engineered T cells expressing a chimeric antigen receptor (CAR) are rapidly emerging a promising new treatment for haematological and…”
    Get full text
    Journal Article
  3. 3

    The roles of small extracellular vesicles in cancer and immune regulation and translational potential in cancer therapy by Qian, Kewen, Fu, Wenyan, Li, Tian, Zhao, Jian, Lei, Changhai, Hu, Shi

    “…Abstract Extracellular vesicles (EVs) facilitate the extracellular transfer of proteins, lipids, and nucleic acids and mediate intercellular communication…”
    Get full text
    Journal Article
  4. 4

    Ig-like ACE2 protein therapeutics: A revival in development during the COVID-19 pandemic by Qian, Kewen, Hu, Shi

    Published in mAbs (01-01-2020)
    “…While the potential therapeutic utility of angiotensin-converting enzyme 2 (ACE2) is well established, the clinical development of ACE2 drugs has been limited,…”
    Get full text
    Journal Article
  5. 5

    CAR Macrophages for SARS-CoV-2 Immunotherapy by Fu, Wenyan, Lei, Changhai, Ma, Zetong, Qian, Kewen, Li, Tian, Zhao, Jian, Hu, Shi

    Published in Frontiers in immunology (23-07-2021)
    “…Targeted therapeutics for the treatment of coronavirus disease 2019 (COVID-19), especially severe cases, are currently lacking. As macrophages have unique…”
    Get full text
    Journal Article
  6. 6

    Engineered soluble ACE2 receptor: Responding to change with change by Li, Guangyao, Qian, Kewen, Zhang, Shuyi, Fu, Wenyan, Zhao, Jian, Lei, Changhai, Hu, Shi

    Published in Frontiers in immunology (18-01-2023)
    “…SARS coronavirus 2 (SARS-CoV-2) invades the human body by binding to major receptors such as ACE2 its S-spike protein, so the interaction of receptor-binding…”
    Get full text
    Journal Article
  7. 7

    The therapeutic potential of exosomes in immunotherapy by Li, Guangyao, Zhang, Shuyi, Zou, Yitan, Ai, Hongru, Zheng, Xinya, Qian, Kewen, Lei, Changhai, Fu, Wenyan

    Published in Frontiers in immunology (08-07-2024)
    “…Exosomes are found in various tissues of the body and carry abundant contents including nucleic acids, proteins, and metabolites, which continuously flow…”
    Get full text
    Journal Article
  8. 8

    Small extracellular vesicles purification and scale-up by Zheng, Xinya, Ai, Hongru, Qian, Kewen, Li, Guangyao, Zhang, Shuyi, Zou, Yitan, Lei, Changhai, Fu, Wenyan, Hu, Shi

    Published in Frontiers in immunology (26-02-2024)
    “…Exosomes are small extracellular vesicles (sEVs) secreted by cells. With advances in the study of sEVs, they have shown great potential in the diagnosis and…”
    Get full text
    Journal Article
  9. 9

    CAR‐T‐cell products in solid tumors: Progress, challenges, and strategies by Qian, Kewen, Li, Guangyao, Zhang, Shuyi, Fu, Wenyan, Li, Tian, Zhao, Jian, Lei, Changhai, Wang, Yuqing, Hu, Shi

    “…T cells engineered to express chimeric antigen receptors (CARs) with specificity toward tumor cells have led to promising outcomes in patients with…”
    Get full text
    Journal Article
  10. 10

    Therapeutic antibodies under development for SARS‐CoV‐2 by Ma, Zetong, Zhu, MengMei, Zhang, Shuyi, Qian, Kewen, Wang, Chuqi, Fu, Wenyan, Lei, Changhai, Hu, Shi

    Published in View (Beijing, China) (01-03-2022)
    “…The world is experiencing one of the most difficult moments in history with COVID‐19, which has rapidly developed into a worldwide pandemic with a significant…”
    Get full text
    Journal Article
  11. 11

    Development and characterization of a novel neutralizing scFv vectored immunoprophylaxis against botulinum toxin type A by Wei, Yongpeng, Li, Guangyao, Wang, Zhuo, Qian, Kewen, Zhang, Shuyi, Zhang, Lingling, Lei, Changhai, Hu, Shi

    Published in Journal of drug targeting (01-12-2024)
    “…Botulinum toxin is a protein toxin secreted by Clostridium botulinum that is strongly neurotoxic. Due to its characteristics of being super toxic, quick…”
    Get full text
    Journal Article
  12. 12

    Exosomes derived from cancer cells relieve inflammatory bowel disease in mice by Zhang, Shuyi, Li, Guangyao, Qian, Kewen, Zou, Yitan, Zheng, Xinya, Ai, Hongru, Lin, Fangxing, Lei, Changhai, Hu, Shi

    Published in Journal of drug targeting (01-11-2024)
    “…Exosome therapy has garnered significant attention due to its natural delivery capabilities, low toxicity, high biocompatibility, and potential for…”
    Get full text
    Journal Article
  13. 13

    Bispecific antibodies targeting EGFR/Notch enhance the response to talazoparib by decreasing tumour-initiating cell frequency by Fu, Wenyan, Li, Guangyao, Lei, Changhai, Qian, Kewen, Zhang, Shuyi, Zhao, Jian, Hu, Shi

    Published in Theranostics (01-01-2023)
    “…Poly ADP ribose polymerase (PARP) inhibitors are mainly used in treating BRCA-mutant cancers, and their application in novel therapies to expand their benefit…”
    Get full text
    Journal Article
  14. 14
  15. 15

    Back Cover: Therapeutic antibodies under development for SARS‐CoV‐2 (View 2/2022) by Ma, Zetong, Zhu, MengMei, Zhang, Shuyi, Qian, Kewen, Wang, Chuqi, Fu, Wenyan, Lei, Changhai, Hu, Shi

    Published in View (Beijing, China) (01-03-2022)
    “…Research on antibody therapy for SARS‐COV‐2 is in the ascendant, including single antibody therapy and multiple antibody combinations. The multi‐drug…”
    Get full text
    Journal Article